Local tumor destruction and liver resection increase overall survival in intermediate/advanced hepatocellular carcinoma patients: evidence from a population-based study

作者全名："Zhang, Yang; Zhang, Yi; He, Taiyu; Liu, Guangliang; Duan, Minjie; Huang, Jian; Huang, Christy; Lowe, Scott; Ke, Dazhi; Liu, Xiaozhu; Cao, Junyi"

作者地址："[Zhang, Yang; Duan, Minjie] Chongqing Med Univ, Coll Med Informat, Chongqing, Peoples R China; [Zhang, Yi; Ke, Dazhi] Chongqing Med Univ, Affiliated Hosp 2, Dept Gen Practice, Chongqing, Peoples R China; [He, Taiyu] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, Chongqing, Peoples R China; [Liu, Guangliang; Liu, Xiaozhu] Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China; [Huang, Jian] Guangxi Univ Chinese Med, Grad Sch, Nanning, Peoples R China; [Huang, Christy] Calif Hlth Sci Univ, Coll Osteopath Med, Clovis, CA USA; [Lowe, Scott] Kansas City Univ, Coll Osteopath Med, Kansas City, MO USA; [Cao, Junyi] First Peoples Hosp Zigong City, Dept Med Qual Control, Zigong, Peoples R China"

通信作者："Ke, DZ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Gen Practice, Chongqing, Peoples R China.; Liu, XZ (通讯作者)，Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China.; Cao, JY (通讯作者)，First Peoples Hosp Zigong City, Dept Med Qual Control, Zigong, Peoples R China."

来源：FRONTIERS IN ENDOCRINOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001045667200001

JCR分区：Q2

影响因子：3.9

年份：2023

卷号：14

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：liver resection; local tumor destruction; hepatocellular carcinoma; survival; nomogram

摘要："BackgroundLiver resection (LR) and local tumor destruction (LTD) are effective treatments, but not commonly recommended for patients with intermediate/advanced hepatocellular carcinoma (HCC). This study aimed to explore whether LR/LTD could improve overall survival (OS) of these patients, and to identify the patients who will most likely benefit from LR/LTD. MethodsData of patients with intermediate/advanced HCC between 2001 and 2018 were extracted from Surveillance, Epidemiology, and End Results database. OS was compared between HCC patients who received LR/LTD and those who did not. A nomogram was constructed for predicting OS, and it was then validated. ResultsA total of 535 eligible patients were included, among which 128 received LR/LTD while 407 did not. Significantly higher OS in patients who received LR/LTD was observed (P<0.001). Based on independent prognostic factors obtained from univariate and multivariate analyses, a nomogram was constructed. The C-indices of nomogram were higher than those of the TNM staging system (training cohort: 0.74 vs. 0.59; validation cohort: 0.78 vs. 0.61). Similarly, areas under receiver operating characteristic curves and calibration curves indicated good accuracy of the nomogram. Decision curve analysis curves revealed good clinical practicability of the nomogram. Furthermore, low-risk patients (nomogram score: 0-221.9) had higher OS compared with high-risk patients (nomogram score: higher than 221.9) (P<0.001). ConclusionLR/LTD significantly improves OS in patients with intermediate/advanced HCC. The nomogram developed in the present study shows high predicating value for OS in patients with intermediate/advanced HCC, which might be useful in selecting patients who are most suitable for LR/LTD."

基金机构：　

基金资助正文：